These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
581 related articles for article (PubMed ID: 28316990)
1. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. Szopa W; Burley TA; Kramer-Marek G; Kaspera W Biomed Res Int; 2017; 2017():8013575. PubMed ID: 28316990 [TBL] [Abstract][Full Text] [Related]
2. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161 [TBL] [Abstract][Full Text] [Related]
3. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents. Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620 [TBL] [Abstract][Full Text] [Related]
4. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882 [TBL] [Abstract][Full Text] [Related]
5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
6. TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review. Zhang X; Katsakhyan L; LiVolsi VA; Roth JJ; Rassekh CH; Bagley SJ; Nasrallah MP Am J Surg Pathol; 2021 Nov; 45(11):1516-1526. PubMed ID: 34366423 [TBL] [Abstract][Full Text] [Related]
7. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults. Goodman AL; Velázquez Vega JE; Glenn C; Olson JJ J Neurooncol; 2022 Jun; 158(2):179-224. PubMed ID: 35648306 [TBL] [Abstract][Full Text] [Related]
8. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
9. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region. Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342 [TBL] [Abstract][Full Text] [Related]
11. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Leibetseder A; Ackerl M; Flechl B; Wöhrer A; Widhalm G; Dieckmann K; Kreinecker SS; Pichler J; Hainfellner J; Preusser M; Marosi C Neuro Oncol; 2013 Jan; 15(1):112-21. PubMed ID: 23223340 [TBL] [Abstract][Full Text] [Related]
12. Molecular Evolution of Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054 [TBL] [Abstract][Full Text] [Related]
13. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189 [TBL] [Abstract][Full Text] [Related]
14. Progress in the application of molecular biomarkers in gliomas. Wang J; Su HK; Zhao HF; Chen ZP; To SS Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
16. Role of Brandes AA; Franceschi E; Paccapelo A; Tallini G; De Biase D; Ghimenton C; Danieli D; Zunarelli E; Lanza G; Silini EM; Sturiale C; Volpin L; Servadei F; Talacchi A; Fioravanti A; Pia Foschini M; Bartolini S; Pession A; Ermani M Oncologist; 2017 Apr; 22(4):432-437. PubMed ID: 28275120 [TBL] [Abstract][Full Text] [Related]
17. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110 [TBL] [Abstract][Full Text] [Related]
18. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470 [TBL] [Abstract][Full Text] [Related]
19. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Shu C; Wang Q; Yan X; Wang J Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907 [TBL] [Abstract][Full Text] [Related]
20. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]